Delve Bio
Test once. Know.
San Francisco, United States · Founded 2022
- Headquarters
- San Francisco, California
- Employees
- 11–50
- Founded
- 2022
- Business Model
- B2B
- Website
- delve.bio
- Last Round
- Series AJun 2023
- Rounds
- 1
About
Delve Bio is a clinical diagnostics company on a mission to revolutionize infectious disease testing by bringing metagenomic next-generation sequencing (mNGS) testing out of the research lab and into the clinic. Founded by leading experts in infectious disease, Delve Bio's platform enables clinicians to test once and know — ending the era of sequential, time-consuming guess-and-test diagnostics. The company's Delve Detect product connects clinicians with medical experts for clinical consults and result interpretation, leveraging mNGS to identify pathogens across a broad range of infectious diseases in a single test.
Summary
Delve Bio is a Biotech company based in San Francisco, United States, founded in 2022. Its most recent funding was a Series A round in Jun 2023. Investors include GV and Section 32.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2023
Investors
Similar Companies
Novel DNA sequencing architecture to scale the ultra low cost whole genome
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company